Envudeucitinib Phase 3 Results Highlight Alumis’ Progress—Robust PASI 90/100 Outcomes and Strong Cash Position Underline Growth Potential

Impressive Clinical Results: Envudeucitinib Delivers Early and Lasting Response in Psoriasis

Alumis Inc. (NASDAQ: ALMS) delivered promising news in its Q1 2026 update, spotlighting Phase 3 clinical results for its lead candidate, envudeucitinib, in moderate-to-severe plaque psoriasis. The late-breaking oral presentation at the 2026 American Academy of Dermatology (AAD) Annual Meeting revealed rapid patient response—with 68.00% and 62.10% achieving PASI 90, and 41.00% and 39.50% hitting PASI 100 by Week 24 in ONWARD1 and ONWARD2 trials, respectively. Substantial improvements emerged as early as Week 4 for scalp psoriasis, with three out of four patients showing "clear or almost clear" scalps by Week 24.

Broadening Impact: Quality of Life and SLE Prospects

The trials also registered early gains in itch relief and patient-reported quality of life, reinforcing envudeucitinib’s profile beyond simple skin clearance. With plans to submit an NDA for psoriasis in Q4 2026 and a pivotal Phase 2b readout in systemic lupus erythematosus (SLE) due in Q3 2026, Alumis appears committed to developing a TYK2 inhibitor “pipeline in a pill,” targeting a spectrum of immune-mediated diseases. Long-term ONWARD3 psoriasis data and additional franchise updates are anticipated in the second half of the year, expanding the outlook for this class of therapies.

Financials Spotlight: Healthy Cash Position and Reduced Operating Expenses

Financially, Alumis stands on a solid foundation:

The company’s cash runway is expected to last into Q4 2027—vital for continued progress of both existing programs and new candidates. Lower R&D and G&A expenses reflect the completion of major trials and prior merger-related costs, helping to control operating losses even as the pipeline expands.

Pipeline Developments: SLE Data Approaching, Strategic Asset Review Announced

Looking ahead, Alumis is maintaining its pace—anticipating Phase 2b SLE data this summer, submitting its NDA for psoriasis on time, and advancing its next clinical candidate into Phase 1 in the second half of the year. The company also completed a strategic review of its lonigutamab program and will explore alternatives for this asset, signifying a focus on its TYK2 franchise.

Investor Takeaway: Positive Data and Solid Financials Position Alumis for Upcoming Milestones

Alumis’ Q1 2026 results combine strong clinical momentum in psoriasis with prudent cost controls and a substantial cash buffer. With key regulatory and clinical milestones on the calendar for both psoriasis and SLE, and a leadership position in TYK2-targeted innovation, the coming quarters could be decisive. Investors and analysts will be watching the NDA submission timing and the SLE topline readout closely, as they will likely shape the commercial landscape for immune-mediated therapies. For those tracking the next wave of biopharmaceutical innovation, Alumis remains a story worth following.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI